| Symbol | GH |
|---|---|
| Name | GUARDANT HEALTH, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical Specialities |
| Address | 505 PENOBSCOT DRIVE, REDWOOD CITY, California, 94063, United States |
| Telephone | +1 855 698-8887 |
| Fax | — |
| — | |
| Website | https://www.guardanthealth.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001576280 |
| Description | Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The companys pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%. Additional info from NASDAQ: |
Director Tariq Musa 🟡 adjusted position in 2.7K shares (2 derivative) of Guardant Health, Inc. (GH) Transaction Date: Jun 17, 2026 | Filing ID: 000016
Read moreDirector POTTER MYRTLE S 🟡 adjusted position in 2.7K shares (2 derivative) of Guardant Health, Inc. (GH) Transaction Date: Jun 17, 2026 | Filing ID: 000002
Read moreDirector MIGNONE ROBERTO 🟡 adjusted position in 2.7K shares (2 derivative) of Guardant Health, Inc. (GH) Transaction Date: Jun 17, 2026 | Filing ID: 000010
Read moreDirector Krognes Steve E. 🟡 adjusted position in 2.7K shares (2 derivative) of Guardant Health, Inc. (GH) Transaction Date: Jun 17, 2026 | Filing ID: 000020
Read moreDirector Joyce Meghan V. 🟡 adjusted position in 0 shares (1 derivative) of Guardant Health, Inc. (GH) Transaction Date: Jun 17, 2026 | Filing ID: 000005
Read moreDirector Hidalgo Medina Manuel 🟡 adjusted position in 2.7K shares (3 derivative) of Guardant Health, Inc. (GH) Transaction Date: Jun 17, 2026 | Filing ID: 000020
Read moreDirector Gadde Vijaya 🟡 adjusted position in 2.7K shares (2 derivative) of Guardant Health, Inc. (GH) Transaction Date: Jun 17, 2026 | Filing ID: 000002
Read moreDirector CLARK IAN T 🟡 adjusted position in 2.7K shares (2 derivative) of Guardant Health, Inc. (GH) Transaction Date: Jun 17, 2026 | Filing ID: 000004
Read moreDirector Azar Alex M II 🟢 acquired 2.7K shares (1 derivative) of Guardant Health, Inc. (GH) Transaction Date: Jun 17, 2026 | Filing ID: 000002
Read more📋 POTTER MYRTLE S (Director) plans to sell 2K shares of Guardant Health, Inc. (at $131.16 each, total $204K) Filed: Jun 22, 2026 | ID: 000676
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07436637 | Guardant Shield Colorectal Cancer Screening | Na | Colorectal Cancer | Not_Yet_Recruiting | 2026-06-30 | 2027-04-01 | ClinicalTrials.gov |
| NCT07620535 | Decision Counseling and Follow-up for Shield+ Patients | — | Colo-rectal Cancer | Not_Yet_Recruiting | 2026-06-01 | 2028-06-01 | ClinicalTrials.gov |
| NCT07004413 | Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RA… | Phase3 | Colorectal Cancer Metastatic | Not_Yet_Recruiting | 2026-01-01 | 2031-01-01 | ClinicalTrials.gov |
| NCT06880055 | Shield Post-Approval Study Protocol | — | Colo-rectal Cancer | Recruiting | 2025-07-14 | 2030-12-01 | ClinicalTrials.gov |
| NCT06444542 | Understanding Patient Preference on Colorectal Cancer Screening Options-PSU | — | Colo-rectal Cancer | Completed | 2024-09-16 | 2025-12-18 | ClinicalTrials.gov |
| NCT05935384 | SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation | — | Non-small Cell Lung Cancer | Recruiting | 2023-10-25 | 2030-12-30 | ClinicalTrials.gov |
| NCT06119425 | Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Prac… | Na | Cancer Colon | Completed | 2023-10-12 | 2025-04-30 | ClinicalTrials.gov |
| NCT05703243 | Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liqu… | — | Stage III Solid Tumors | Unknown | 2023-02-01 | 2025-01-01 | ClinicalTrials.gov |
| NCT05716477 | Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved… | — | Colorectal Carcinoma | Completed | 2022-12-23 | 2024-11-30 | ClinicalTrials.gov |
| NCT05117840 | Screening for High Frequency Malignant Disease | — | Lung Cancer | Active_Not_Recruiting | 2022-01-13 | 2026-12-31 | ClinicalTrials.gov |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Bladder Carcinoma | Recruiting | 2021-09-07 | 2029-08-01 | ClinicalTrials.gov |
| NCT05641870 | Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanc… | — | Lung Cancer | Unknown | 2021-02-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT04497285 | Real World Study Using Comprehensive Genomic Data on the Next Treatment Decisio… | — | Metastatic Breast Cancer | Active_Not_Recruiting | 2020-10-20 | 2026-11-30 | ClinicalTrials.gov |
| NCT04436393 | Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Br… | — | Advanced Breast Cancer | Completed | 2020-07-02 | 2022-03-17 | ClinicalTrials.gov |
| NCT04136002 | Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode | — | Colorectal Cancer | Active_Not_Recruiting | 2019-10-08 | 2027-08-05 | ClinicalTrials.gov |
| NCT04087473 | Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC | — | Non-small Cell Lung Cancer | Completed | 2019-08-23 | 2025-12-31 | ClinicalTrials.gov |
| NCT03625557 | Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Recor… | — | Non-Hematologic Malignancy | Completed | 2019-04-30 | 2020-04-16 | ClinicalTrials.gov |
| NCT03477474 | Registry of Guardant360® Use and Outcomes In People With Advanced Cancer | — | Non-small Cell Lung Cancer Metastatic | Terminated | 2018-04-06 | 2019-09-01 | ClinicalTrials.gov |
| NCT03774758 | Biomarkers for Risk Stratification in Lung Cancer | — | Nodule Solitary Pulmonary | Recruiting | 2017-12-17 | 2030-12-31 | ClinicalTrials.gov |
| NCT03791034 | Cell Free DNA for the Diagnosis and Treatment in Early NSCLC | — | Non-small Cell Lung Cancer | Recruiting | 2017-08-28 | 2026-12-31 | ClinicalTrials.gov |
| NCT02967770 | Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Meta… | Phase2 | Metastatic Pancreatic Cancer | Withdrawn | 2016-11-01 | 2018-08-30 | ClinicalTrials.gov |
| NCT03248089 | Spanish Lung Liquid vs. Invasive Biopsy Program (SLLIP) | — | Lung Cancer | Completed | 2016-07-01 | 2019-01-01 | ClinicalTrials.gov |
| NCT03746262 | Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-S… | — | Non Small Cell Lung Cancer | Completed | 2016-05-13 | 2018-08-10 | ClinicalTrials.gov |
| NCT03615443 | Noninvasive vs. Invasive Lung Evaluation | — | Non-Small Cell Lung Cancer | Completed | 2016-02-12 | 2020-11-23 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Guardant Health ct-DNA LUNAR assay | Other | Preclinical | Nodule Solitary Pulmonary | RECRUITING | NCT03774758 |
| Decision Counseling Session | Other | Preclinical | Colo-rectal Cancer | NOT_YET_RECRUITING | NCT07620535 |
| Blood Sample Collection | Other | Approved | Colorectal Cancer | NOT_YET_RECRUITING | NCT07436637 |
| Screening Reminder | Other | Approved | Colorectal Cancer | NOT_YET_RECRUITING | NCT07436637 |
| Standard of Care Second Line Therapy | Drug | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT02967770 |
| Molecularly Tailored Second Line Therapy | Drug | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT02967770 |
| Guardant360 | Other | Preclinical | Lung Cancer | COMPLETED | NCT03248089 |
| Guardant360 | Other | Preclinical | Non-Small Cell Lung Cancer | COMPLETED | NCT03615443 |
| Guardant360 test | Other | Preclinical | Advanced Breast Cancer | COMPLETED | NCT04436393 |
| Genomic and methylation analysis in liquid biopsy | Other | Preclinical | Lung Cancer | UNKNOWN | NCT05641870 |
| Chemoradiation treatment regimen and maintenance (if amenable) | Drug | Preclinical | Lung Cancer | UNKNOWN | NCT05641870 |
| Characterization of the tumoral tissue genomic alterations | Other | Preclinical | Lung Cancer | UNKNOWN | NCT05641870 |
| Sample collection | Other | Preclinical | Lung Cancer | UNKNOWN | NCT05641870 |
| EORTC QLQ-30 | Other | Preclinical | Stage III Solid Tumors | UNKNOWN | NCT05703243 |
| Comprehensive liquid molecular panel test | Other | Preclinical | Stage III Solid Tumors | UNKNOWN | NCT05703243 |
| Survey Administration | Other | Preclinical | Colorectal Carcinoma | COMPLETED | NCT05716477 |
| Biospecimen Collection | Other | Preclinical | Colorectal Carcinoma | COMPLETED | NCT05716477 |
| Guardant Health ct-DNA LUNAR assay | Other | Preclinical | Nodule Solitary Pulmonary | RECRUITING | NCT03774758 |
| Guardant360 ctDNA assay | Other | Phase PHASE3 | Colorectal Cancer Metastatic | NOT_YET_RECRUITING | NCT07004413 |
| FOLFIRI+cetuximab | Other | Phase PHASE3 | Colorectal Cancer Metastatic | NOT_YET_RECRUITING | NCT07004413 |
| blood sample collection and collection of tumor tissue block | Other | Preclinical | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04497285 |
| Guardant360 | Other | Preclinical | Non-small Cell Lung Cancer | RECRUITING | NCT05935384 |
| Guardant Reveal | Other | Preclinical | Bladder Carcinoma | RECRUITING | NCT05059444 |
| Pemetrexed | Other | Phase PHASE2 | Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT04410796 |
| Carboplatin | Other | Phase PHASE2 | Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT04410796 |
| Osimertinib | Other | Phase PHASE2 | Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT04410796 |
| blood-based CRC screening | Other | Approved | Cancer Colon | COMPLETED | NCT06119425 |
| Guardant Shield | Other | Preclinical | Colo-rectal Cancer | COMPLETED | NCT06444542 |
| Shield Blood Test for colo-rectal cancer Screening | Other | Preclinical | Colo-rectal Cancer | RECRUITING | NCT06880055 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Low-dose CT scan | Other | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| Blood Sample Collection | PROCEDURE | Approved | Colorectal Cancer | NOT_YET_RECRUITING | NCT07436637 |
| Screening Reminder | BEHAVIORAL | Approved | Colorectal Cancer | NOT_YET_RECRUITING | NCT07436637 |
| FOLFIRI+cetuximab | DRUG | Phase PHASE3 | Colorectal Cancer Metastatic | NOT_YET_RECRUITING | NCT07004413 |
| Guardant Shield | BEHAVIORAL | Preclinical | Colo-rectal Cancer | COMPLETED | NCT06444542 |
| Survey Administration | OTHER | Preclinical | Colorectal Carcinoma | COMPLETED | NCT05716477 |
| Biospecimen Collection | PROCEDURE | Preclinical | Colorectal Carcinoma | COMPLETED | NCT05716477 |
| EORTC QLQ-30 | OTHER | Preclinical | Stage III Solid Tumors | UNKNOWN | NCT05703243 |
| Chemoradiation treatment regimen and maintenance (if amenable) | DRUG | Preclinical | Lung Cancer | UNKNOWN | NCT05641870 |
| Sample collection | PROCEDURE | Preclinical | Lung Cancer | UNKNOWN | NCT05641870 |
| Low-dose CT scan | DEVICE | Preclinical | Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05117840 |
| blood sample collection and collection of tumor tissue block | OTHER | Preclinical | Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | NCT04497285 |
| Pemetrexed | DRUG | Phase PHASE2 | Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT04410796 |
| Carboplatin | DRUG | Phase PHASE2 | Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT04410796 |
| Osimertinib | DRUG | Phase PHASE2 | Metastatic Non-small Cell Lung Cancer | RECRUITING | NCT04410796 |
| Standard of Care Second Line Therapy | DRUG | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT02967770 |
| Molecularly Tailored Second Line Therapy | OTHER | Phase PHASE2 | Metastatic Pancreatic Cancer | WITHDRAWN | NCT02967770 |